Masimo Corporation
Masimo Reports Strong Q3 2024 Financial Results
Summary
Masimo Corporation reported strong third-quarter 2024 financial results with consolidated revenue of $504.6 million, an 11.5% increase in healthcare revenue to $343.3 million, and a non-GAAP net income of $52.9 million, or $0.98 per diluted share. The company also updated its full-year 2024 guidance, raising non-GAAP EPS to a range of $3.95 to $4.10. The third-quarter results were driven by the core healthcare segment, and the company expects to achieve significant long-term growth potential. A conference call with the CFO was held to discuss the financial results and updated outlook.
Get alerts for MASI
Be first to know when Masimo Corporation files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Masimo Corporation
Masimo Corporation is a global leader in noninvasive monitoring technologies, specifically focusing on developing innovative medical devices that improve patient outcomes and reduce the cost of care. The company's flagship product line includes advanced signal processing pulse oximetry devices, which are pivotal in accurately measuring oxygen levels, pulse rate, and other vital signals without the need for invasive procedures. Masimo's technology is widely adopted across various healthcare settings including hospitals, outpatient treatment centers, and alternative care sites, enhancing patient monitoring and aiding clinicians in detecting potential health issues more efficiently. Besides, Masimo’s products are recognized for their precision and reliability, demonstrating robustness even in challenging clinical environments where motion and low perfusion can affect monitoring accuracy. The corporation is committed to expanding its technological suite, covering a spectrum of health monitoring solutions that contribute to improved healthcare practices globally. Based in Irvine, California, Masimo's ongoing innovation continues to set benchmarks in the healthcare industry, influencing a wide range of sectors from emergency care to surgical and critical care monitoring.
Official SEC Documents
Advertisement